Go to main content
R&D JW, leading global new drug development
Home

Pipeline

Our Pipeline at a Glance

19

Compounds in
Development

Disease Area

Cancer Immunological disease Cardiovascular system
and metabolic diseases
Regenerative medicine Rare Diseases Eye diseases
In the Pipeline
Pre-Clinical Phase 1 Phase 2 Phase 3 Approval

Cancer

Project A1
WNT inhibitor
X
Project A1 – Pre-Clinical
Mode-of-Action:
WNT inhibitor (po)
Indication:
Solid cancers
​Partners:​
Additional Information:
Orally available
Drug Classification:
Small molecule
Project B1
X
Project B1 – Pre-Clinical​
Mode-of-Action:
Indication:
Cancer
​Partners:​
Additional Information:
First-in-class drug
Drug Classification:
Small molecule
CWP291
WNT inhibitor
X
CWP291 – Phase 1
Mode-of-Action:
WNT inhibitor (iv)
Indication:
Cancers (AML, Multiple Myeloma)
Cancer (Gastric cancer)
​Partners:​
Additional Information:
Global/Domestic Phase 1
Drug Classification:
Small molecule
Project B2
X
Project B2 – Pre-Clinical​
Mode-of-Action:
Indication:
Cancer
​Partners:​
Additional Information:
Immuno-oncology drug
Drug Classification:
Small molecule
Project B3
X
Project B3 – Pre-Clinical​
Mode-of-Action:
Indication:
Cancer
​Partners:​
Additional Information:
Immuno-oncology drug
Drug Classification:
Small molecule
Project B4
X
Project B4 – Pre-Clinical
Mode-of-Action:
Indication:
Cancer
​Partners:​
Additional Information:
Antibody-drug conjugate
Drug Classification:
Large molecule

Immunological disease

Project A2
WNT inhibitor
X
Project A2 – Pre-Clinical​
Mode-of-Action:
WNT inhibitor
Indication:
Asthma
IPF (Idiopathic Pulmonary Fibrosis)
​Partners:​
Additional Information:
Drug Classification:
Small molecule
Project B5
X
Project B5 – Pre-Clinical
Mode-of-Action:
Indication:
Immunological disease
​Partners:​
Singapore A*STAR
Additional Information:
Drug Classification:
Small molecule
JWP1601
H4R antagonist
X
JWP1601 – phase 1
Mode-of-Action:
Histamine H4 receptor antagonist
Indication:
Atopic dermatitis
​Partners:​
Leo Pharma
Additional Information:
Drug Classification:
Small molecule
URC102
X
URC102 – phase 2
Mode-of-Action:
Urate anion exchanger 1 inhibitor
Indication:
Gout
​Partners:​
Simcere Pharmaceutical
Additional Information:
Drug Classification:
Small molecule

Cardiovascular system and
metabolic diseases

LIVALO
X
Livalo Tablet - Launch
Mode-of-Action:
HMG-CoA reductase
Indication:
hyperlipidemia
Administration
Orally once daily
Storage:
Room temperature (1-30℃)
Drug substance:
Pitavastatin Ca
Strength:
1, 2, 4 mg
Dosage form:
Round, film coated tablet
LIVALO E
X
LIVALO E Tablets - Phase 3
Mode-of-Action:
HMG-CoA reductase,
Cholesterol absorption inhibitor
Indication:
hyperlipidemia
Administration:
Orally once daily
Storage:​
Room temperature (1-30℃)
Drug substance:
Pitavastatin Ca/Ezetimibe
Strength:
2/10, 4/10 mg
Dosage form:
Round, film coated tablet
LIVALO V
X
Livalo V Tablet - Launch
Mode-of-Action:
HMG-CoA reductase, Angiotensin-receptor blocker
Indication:
hyperlipidemia, hypertension
Administration:
Orally once daily
Storage:​
Room temperature (1-30℃)
Drug substance:
Pitavastatin Ca/Valsartan
Strength:
2/80, 4/80, 2/160, 4/160 mg
Dosage form:
2/80, 4/80 mg: Round, film coated tablet
2/160, 4/160 mg: Rectangle, film coated tablet
J-DART
X
J-dart Tablets – Launch
Mode-of-Action:
5-alpha reductase inlibitor
Indication:
Benign prostatic
hyperplasia(BPH)
Androgenic alopecia(only in Asian countries)
Administration:
Orally once daily
Storage:​
Room temperature (1-30℃)
Drug substance:
Dutasteride
Strength:
0.5mg
Dosage form:
Rectangle, film coated tablet

Regenerative medicine

CWL080061
X
CWL080061 – Pre-Clinical
Mode-of-Action:
WNT activator
Indication:
Hair regeneration
Partners:​
Additional information:
Drug Classification:
Small molecule
Project A3
WNT activator
X
Project A3 – Pre-Clinical
Mode-of-Action:
WNT activator
Indication:
Regenerative medicine
Partners:​
Additional information:
Drug Classification:
Small molecule

Rare Diseases

Project A4
WNT activator
X
Project A4 – Pre-Clinical
Mode-of-Action:
WNT activator
Indication:
central disease
Partners:​
Additional information:
Drug Classification:
Small molecule
HEMLIBRA
hemophilia
X
Hemlibra
Mode-of-Action:
Bispecfic factor Ixa and factor X-directed antibody restores the function of missing activated factor VIII
Indication:
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with severe hemophilia A (congenital factor VIII deficiency)
Administration:
Subcutaneous injection, QW, Q2W, Q4W
Storage:
2~8℃
Drug substance:
Emiciczumab
Strength:
30mg/10.ml, 60mg/0.4ml, 90mg/0.6ml, 105mg/0.7ml, 150mg/1.0ml
Partners:​
Chugai

Eye diseases

Project A5
H4R antagonist
X
Project A5 – Pre-Clinical
Mode-of-Action:
Histamine H4 Receptor antagonist
Indication:
AMD (Age-related macular degeneration)
AC (Allergic conjunctivitis)
Partners:​
Additional information:
Drug Classification:
Small molecule
X
Cancer
JW’s vision in anti-cancer therapies is to change the paradigm of cancer treatment and improve the quality of life for cancer patients.

To this end, JW is focusing on the research and development of targeted anticancer and immune cell therapies.

Beginning with the first development of dendritic cell-based immune cell therapies in metastatic renal cell carcinoma, JW has increased its understanding of immuno-oncology through differentiated clinical development programs for a variety of carcinomas.

JW is also continuing to research biomarkers to predict which patients will benefit the most from anticancer and immune cell therapies.

In addition to the immuno-oncology portfolio, JW is investigating the signaling mechanisms involved in cancer development and developing a cancer treatment portfolio, specifically targeting Wnt and STAT signaling systems.
X
Cardiovascular system and metabolic diseases
Cardiovascular disease includes any disease related to the heart or blood vessels.

JW is looking for a treatment that can improve cardiovascular management, focusing on hyperlipidemia and hypertension for patients who are threatened with life due to cardiovascular and metabolic diseases.

JW is also committed to ultimately improving quality of life and addressing unmet medical needs.

Livalo (component name pitavastatin) has been shown to be a safe treatment without the risk of diabetes, as it not only lowers the incidence of major cardiac events but also improves blood glucose control in clinical trials in Korean patients with acute infarction.

In addition, JW is developing various fixed-dose combination products using its technology to allow the patients with hyperlipidemia and hypertension to take the necessary drugs at once, and to increase the convenience of administration.
X
Immunological disease
JW continues to develop its expertise in immunology and is striving to develop innovative medicines for patients with diseases such as atopy, gout, asthma and idiopathic pulmonary fibrosis.

JW's goal is to develop treatments that act on the molecular level to solve the root causes of chronic inflammatory diseases not managed by conventional symptom-relieving therapies.
X
Regenerative medicine
Regenerative medicine is the field of medicine that replaces or regenerates human cells, tissues and organs to restore their original function.

JW's goal is to regenerate damaged areas by activating the body's own recovery mechanisms of previously unrecoverable tissues and organs.

JW is particularly interested in Wnt signals, which are involved in stem cell growth, differentiation and related signaling pathways, and is working on the development of therapeutics applicable to hair follicle regeneration, muscle and brain diseases, etc.
X
Rare Diseases
Rare disease is defined as a disease in which rare population is less than 20,000 or difficult to diagnose due to rare disease management law.

JW is working to develop effective therapies for patients with rare diseases including hemophilia.
X
Eye diseases
Vision decline is a major health and social problem affecting more than one billion people around the world. Potentially limiting social interaction and independence, it affects patients' ability to work and leads to the development of depression and anxiety.

JW is currently working on the discovery of new therapies for the treatment of diseases such as age-related macular degeneration (AMD) and allergic conjunctivitis (AC) based on molecular-level mechanisms.
X
Diagnose
JWBS-R001, Phase 1
Novel biomarker for sepsis diagnosis
  • WRS, Tryptophanyl tRNA synthetase (53KDa)
  • Rapidly secret upon infection to prime innate immunity
  • WRS is a reliable, specific and sensitive biomarker for sepsis
    (Ahn YH et al., Nature Microbiology, 2016)
POCT
  • Central lab quality at the point of care.
  • Quantitative measurement of 6 analyses in parallel.
  • A fully automatic immunoassay analyzer with chemiluminescence technology.
  • The data within less than 20 minutes.
Patent
  • Composition and method for detecting a diagnostic marker for sepsis using tryptophanyl-tRNA synthetase (2016. 03. 02)
  • Antibodies specifically binding to WRS protein and uses thereof (2019. 07. 18)

JWBS-R002, Preclinical
Novel biomarker for pancreatic cancer diagnosis
  • CFB, Complement factor B (93KDa)
  • A combination of CFB and CA19-9 improved diagnostic accuracy of pancreatic cancer
  • The world’s first multi-biomarker diagnostic kit with which pancreatic cancer.
Patent
  • Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer (2014. 05. 12)
X
Nutrition
WINUF
  • Indication : Nutritional Nutrition
  • Ingredient : Dextrin/Amino acid/Lipid emulsion, 3 Chamber system
  • Volume : 1085mL, 1435 mL, 1820mL, 1450mL, 2020mL
  • Packing material : Non-PVC plastic bag
Everamin injection
  • Indication : Nutritional Nutrition
  • Ingredient : amino acid (glycine, arginine, isoleucine, etc.)
  • Volume : 100/250mL
  • Packing material : Non-PVC plastic bag
Acetapen injection
  • Indication : Pain and fever
  • Ingredient : Acetaminophen 10mg
  • Volume : 100mL
  • Packing material : Non-PVC plastic bag
Levetiram injection
  • Indication : Anticonvulsants
  • Ingredient : Levitracetam 1000mg
  • Volume : 110mL
  • Packing material : Non-PVC plastic bag